CNR2 and breast cancer: However, these studies assessing breast cancer progression were using CB2 agonist administered within 7 days of tumor transplant with small tumor volumes under 100 mm3 using peritumoral (Elbaz et al., 2017) or systemic (Hanlon et al., 2016) administration.